Treatment
Allogeneic CAR-T clinical trials
We’re tracking 136 recruiting studies that include Allogeneic CAR-T, each written for real people, not researchers, below.
Recruiting studies
- NCT07760454RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed multiple myeloma
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
Suzhou, JiangsuAges 18 years+ - NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT06717022Recruiting
CHT102 for mesothelin-positive advanced solid tumors
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70 - NCT06718270RecruitingEarly Phase 1
Study of CT0596 for Relapsed or Refractory Myeloma
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07564401RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Lung Cancer
This study tests DJI136, a new type of cell therapy that trains your immune cells to fight small cell lung cancer. The therapy targets a protein called DLL3 found on cancer cells. It's designed for patients whose cancer has returned or progressed after initial chemotherapy and immunotherapy.
Lexington, KentuckyAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT07395479RecruitingEarly Phase 1
CAR-T therapy study for advanced blood and solid cancers
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06834529RecruitingPhase 1/Phase 2
CAR-T cell therapy for returning B-cell leukemia or lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Beijing, Beijing MunicipalityAges 14–75 - NCT06850285Recruiting
CD30 CAR-T for relapsed or refractory CD30+ lymphoma
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
Taiyuan, ShangxiAges 15–80 - NCT07350863RecruitingPhase 1
U69-CART cells for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma
This trial tests a new type of cell therapy (U69-CART cells) that targets a specific protein (CCR9) found on leukemia cells in people whose T-cell acute lymphoblastic leukemia or lymphoma has come back or hasn't responded to standard treatments. The goal is to see if this therapy can help control the disease.
Suzhou, JiangsuAges 15–75 - NCT07248163Recruiting
Universal CAR-T cell therapy for non-Hodgkin lymphoma
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
ShanghaiAges 18 years+ - NCT07212335RecruitingEarly Phase 1
Stem cells for low blood counts after CAR-T
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
TianjinAges 18 years+ - NCT07198867RecruitingPhase 1
A-CAR028 for relapsed or refractory AML
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07135466RecruitingPhase 1/Phase 2
Anti-CD22 CAR T-cell therapy for B-cell blood cancers
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
Ramat Gan, GAges 1–80 - NCT07115745RecruitingPhase 1
Donor CAR T cells for severe autoimmune diseases
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT06912152RecruitingPhase 1
Testing MT027 for advanced belly-lining cancers
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70
Common questions
- Are there clinical trials studying Allogeneic CAR-T?
- Yes. Clin2 currently lists 136 recruiting studies that include Allogeneic CAR-T, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Allogeneic CAR-T trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Allogeneic CAR-T an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Allogeneic CAR-T or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.